GlassScriptPhysician profile
Shibu Skaria
NPI 1821170093
$1,117.42
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $468.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $142.14 | 2019 | |
| Allergan, INC. | $141.88 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $70.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.57 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.90 | 2019 | |
| Genentech USA, INC. | $45.15 | 2019 | |
| Pfizer INC. | $36.59 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $22.11 | 2019 | |
| Advanced Respiratory, INC | $21.91 | 2019 | |
| Genzyme Corporation | $17.93 | 2019 | |
| Mylan Specialty L.P. | $16.92 | 2019 | |
| Shire North American Group INC | $16.68 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shibu Skaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.